CG Oncology to Present Two Programs at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

IRVINE, Calif .– (COMMERCIAL THREAD) – CG Oncology, Inc., a clinical-stage biotechnology company focused on the development of oncolytic immunotherapies for patients with advanced cancer, today announced the acceptance of an oral presentation and a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held virtually and in person in Washington, DC, November 10-14, 2021.

CG Oncology to present preliminary safety and efficacy data from CORE1, an ongoing Phase 2 clinical trial of CG0070 in combination with KEYTRUDA® (pembrolizumab), for the treatment of patients with non-invasive bladder cancer (NMIBC) not responding to Bacillus Calmette-Guérin (BCG).

In a previously announced clinical collaboration with Merck for the study of CG0070 used in combination with pembrolizumab, the goal of CORE1, which will enroll up to 35 patients, is to assess safety and efficacy. of CG0070 plus KEYTRUDA for the treatment of BCG-insensitive NMIBCs.

You can find more information about the study at www.clinicaltrials.gov (NCT04387461).

The details of the oral presentation are as follows:

CORE1: Single-arm, phase 2 study of CG0070 in combination with pembrolizumab in patients with non-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG)

Abstract Number: 955

Presenter: Roger Li, MD, Moffitt Cancer Center

Session date and time: Saturday, November 13, 2021 from 12:15 p.m. to 12:30 p.m. EST

Category: Last minute oral summary session

In addition, CG Oncology will present an overview of the design and methodology of the BOND3 trial, an ongoing global Phase 3 trial with CG0070 as monotherapy for the treatment of patients with NMIBC unresponsive to BCG. The objective of BOND3, which will recruit 110 patients, is to assess the safety and efficacy of CG0070 as monotherapy for the treatment of BCG-insensitive NMIBC.

You can find more information about the study at www.clinicaltrials.gov (NCT04452591).

The details of the poster presentation are as follows:

A single-arm, phase 3 study of CG0070 in subjects with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG)

Abstract number: 426

Presenter: Edward Uchio, MD, UC Irvine Health, Department of Urology

Session date and time: Friday, November 12, 2021 and Saturday, November 13, 2021 from 7:00 a.m. to 8:30 p.m. EST

Category: Poster abstracts session

Full summaries of both presentations will be available on the SITC website on November 10, 2021.

About CG Oncology

CG Oncology is a clinical-stage biotechnology company focused on developing the next evolution in oncolytic immunotherapy for patients with advanced cancer. Our lead candidate, CG0070, is a selective oncolytic immunotherapy in a phase 3 trial with CG0070 as monotherapy for the treatment of BCG-insensitive NMIBC, and a combined phase 2 study of CG0070 with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO® (nivolumab), and additional indications in other solid tumors are being sought with CG0070 in combination with other endpoint inhibitors. immune control. At CG Oncology, we aim to take the next evolutionary step by providing innovative cancer care to millions of patients in need around the world. Learn more about www.cgoncology.com.


Source link

Comments are closed.